Management of the Complex Type 2 Diabetes Patient with Kidney Disease | Module 2 – Cardiorenal Protection in Type 2 Diabetes: The Role of SGLT2i and GLP1-RA

CAN-eng

$0

free

CCCEP

15 min

Diabetes, Nephrology

0.33 Credits

This course is expired! Browse All Courses
LEARN MORE

Course Description

This video helps pharmacists understand the role of sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA) in cardiorenal protection for people with type 2 diabetes. The goal is to review the use of SGLT2i and GLP1-RA for these patients, and help pharmacists apply effective counselling for the management of people with type 2 diabetes and chronic kidney disease.

This learning activity has received financial support from Janssen Inc in the form of educational grant

Course Details

Expiry Date: 2023-08-16

Professions: Pharmacy

Faculty

Rick Siemens, BScPharm, B.Sc. Biol., CDE, CPT, APA – Pharmacist
Parveen Gill, BScPharm, CDE, CAE, CTH, APA – Pharmacist
Anita Brown, BScPharm, CDE – Pharmacist
John Papastergiou, BScPharm, B.Sc. – Pharmacist

Accreditation

This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 0.33 CEU(s).

CCCEP File Number: 1066-2022-3453-I-P

Learning Objective(s)

Upon completion of this continuing education program participants will be better able to:
  • Understand the role of SGLT2i and GLP1-RA in cardiorenal protection of people with type 2 diabetes
  • Describe the mechanism of action of SGLT2i and GLP1-RA for cardiorenal protection in people with type 2 diabetes
  • Illustrate the use of pharmacotherapy for cardiorenal protection in people with type 2 diabetes
This course is expired! Browse All Courses